Income statement, balance sheet and cash flow statement for the last 2 fiscal years, taken from the XBRL data Evommune, Inc. files with the SEC in its annual reports.
In USD millions, except per-share amounts. Outflows in the cash flow statement are negative.
Income statement
FY2025
FY2025
Revenue
7
13
Research and development
64.2
74
General and administrative
12.8
20
Operating expenses
77
94.1
Operating income
-70
-81.1
Interest income
3.24
3.32
Other non-operating income
3.21
12.2
Pre-tax income
-68.3
-68.9
Income tax
0
0
Net income
-66.8
-68.9
EBITDA
-69.5
-80.5
EPS, basic
-45.29
-11.22
EPS, diluted
-45.29
-11.22
Shares, basic (weighted)
1.51
6.14
Shares, diluted (weighted)
1.51
6.14
Balance sheet
FY2025
FY2025
Cash and equivalents
16.3
44.1
Short-term investments
55.8
105
Other current assets
1.95
4.28
Total current assets
74
153
Property, plant and equipment
1.33
0.99
Lease right-of-use assets
0.47
1.47
Long-term investments
67.5
Other non-current assets
0.06
0.1
Total assets
76.1
225
Accounts payable
8.26
7.76
Accrued liabilities
6.73
9.55
Deferred revenue
3
Total current liabilities
28
17.9
Lease liabilities
1.29
Other non-current liabilities
0.54
Total liabilities
28.5
19.4
Paid-in capital
7.98
427
Retained earnings
-152
-221
Shareholders' equity
-144
206
Total equity
-144
206
Total liabilities and equity
76.1
225
Shares outstanding
1.55
31.5
Cash flow statement
FY2025
FY2025
Net income
-66.8
-68.9
Depreciation and amortization
0.5
0.6
Stock-based compensation
1.72
5.86
Change in payables
6.51
-0.84
Cash from operations
-58.2
-76.4
Capital expenditures
-0.09
-0.24
Purchases of investments
-90.3
-199
Sales and maturities of investments
86.4
84.1
Cash from investing
-3.99
-115
Stock issued
0.01
0.01
Cash from financing
49.4
221
Net change in cash
-12.8
29
Free cash flow
-58.3
-76.7
Interest paid
0.03
0.01
Key metrics
Worked out from the statements above. Latest values use the trailing twelve months to June 30, 2026; growth uses fiscal years. Valuation uses the share price of $8.49 on September 25, 2026.
Profitability
Metric
Value
How it is calculated
Operating margin
-1,019.0%
Operating income / revenue.
EBITDA margin
-1,010.0%
EBITDA (operating income + depreciation and amortization) / revenue.
Net margin
-946.7%
Net income / revenue.
FCF margin
-746.5%
Free cash flow (cash from operations - capital expenditures) / revenue.
Operating cash flow margin
-741.5%
Cash from operations / revenue.
Return on equity (ROE)
-34.1%
Net income / average shareholders' equity (opening and closing). Not shown when equity is negative.
Return on assets (ROA)
-31.4%
Net income / average total assets.
Return on invested capital (ROIC)
-37.0%
Approximation: operating income x (1 - tax rate) / average (total debt + equity - cash). Tax rate is the effective rate when between 0% and 50%, else 21%.
R&D / revenue
837.7%
Research and development expense / revenue.
Stock-based pay / revenue
128.1%
Stock-based compensation (from the cash flow statement) / revenue.
Capex / revenue
5.0%
Capital expenditures / revenue.
D&A / revenue
9.4%
Depreciation and amortization / revenue.
Growth
Metric
Value
How it is calculated
Revenue growth, 1y
85.7%
Revenue vs the same period a year earlier. Only from a positive base.
Total assets growth, 1y
195.8%
Total assets vs the same period a year earlier. Only from a positive base.
Share count change, 1y
306.9%
Change in diluted weighted shares vs a year earlier. Negative means buybacks shrank the share count; positive means dilution.
Balance sheet health
Metric
Value
How it is calculated
Current ratio
11.7x
Current assets / current liabilities.
Quick ratio
11.5x
(Cash + short-term investments + receivables) / current liabilities.
Cash ratio
11.5x
(Cash + short-term investments) / current liabilities.
Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
Revenue per share
$0.28
Revenue / diluted weighted shares.
FCF per share
-$2.07
Free cash flow / diluted weighted shares.
Operating cash flow per share
-$2.05
Cash from operations / diluted weighted shares.
Book value per share
$7.65
Shareholders' equity / shares outstanding (diluted weighted shares when not reported).
Market cap + total debt - cash - short-term investments.
P/S
30.8x
Market cap / revenue.
P/B
1.11x
Market cap / shareholders' equity. Only when equity is positive.
Price / tangible book
1.11x
Market cap / tangible book value, when positive.
EV/Sales
10.7x
Enterprise value / revenue.
FCF yield
-24.2%
Free cash flow / market cap.
Earnings yield
-30.7%
Net income / market cap (the inverse of P/E).
What was Evommune, Inc.'s revenue in fiscal 2025?
Evommune, Inc. reported revenue of $13.0M for fiscal 2025, 85.7% higher than the year before.
Was Evommune, Inc. profitable in fiscal 2025?
No. It reported a net loss of $68.9M.
How much free cash flow did Evommune, Inc. generate in fiscal 2025?
Cash from operations of $76.4M minus capital expenditures of $235.0K left free cash flow of -$76.7M.
Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.